TScan Therapeutics Inc.

AI Score

XX

Unlock

1.44
0.14 (10.77%)
At close: Apr 17, 2025, 3:59 PM
1.49
3.75%
Pre-market: Apr 21, 2025, 09:07 AM EDT
10.77%
Bid 1.44
Market Cap 75.33M
Revenue (ttm) 2.82M
Net Income (ttm) -127.5M
EPS (ttm) -1.26
PE Ratio (ttm) -1.14
Forward PE -1.15
Analyst Buy
Ask 1.5
Volume 1,012,512
Avg. Volume (20D) 429,469
Open 1.31
Previous Close 1.30
Day's Range 1.30 - 1.55
52-Week Range 1.02 - 9.69
Beta 1.08

About TCRX

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors....

Industry Biotechnology
Sector Healthcare
IPO Date Jul 16, 2021
Employees 194
Stock Exchange NASDAQ
Ticker Symbol TCRX
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for TCRX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 594.44% from the latest price.

Stock Forecasts

Next Earnings Release

TScan Therapeutics Inc. is scheduled to release its earnings on May 12, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription